“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China – Biogen

1. “LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China  Biogen
2. Promising Alzheimer’s drug gets green light from Australian regulators  Australian Broadcasting Corporation
3. New hope for…

Continue Reading